CERO (CERo Therapeutics Holdings) Total Liabilities: $11.46 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CERo Therapeutics Holdings Total Liabilities?

CERo Therapeutics Holdings CERO -12.75% Total Liabilities is $11.46 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

CERo Therapeutics Holdings's Total Liabilities for the quarter that ended in Mar. 2026 was $11.46 Mil.

CERo Therapeutics Holdings's quarterly Total Liabilities increased from Sep. 2025 ($8.46 Mil) to Dec. 2025 ($9.09 Mil) and increased from Dec. 2025 ($9.09 Mil) to Mar. 2026 ($11.46 Mil).

CERo Therapeutics Holdings's annual Total Liabilities declined from Dec. 2023 ($47.18 Mil) to Dec. 2024 ($8.10 Mil) but then increased from Dec. 2024 ($8.10 Mil) to Dec. 2025 ($9.09 Mil).


CERo Therapeutics Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for CERo Therapeutics Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings Total Liabilities Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
47.60 46.22 47.18 8.10 9.09

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.32 7.84 8.46 9.09 11.46

CERo Therapeutics Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CERo Therapeutics Holdings's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=3.641--5.446
=9.09

CERo Therapeutics Holdings's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.327+(0.137+4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=11.46

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2.205--9.259
=11.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $11.46 Mil mean?
CERo Therapeutics Holdings (CERO) has a Total Liabilities of $11.46 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CERo Therapeutics Holdings and its competitors.
Is CERo Therapeutics Holdings' Total Liabilities too high?
CERo Therapeutics Holdings' current Total Liabilities is $11.46 Mil.
How does CERo Therapeutics Holdings' Total Liabilities compare to WINT and LIPO?
CERo Therapeutics Holdings' Total Liabilities of $11.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CERo Therapeutics Holdings and its competitors. CERo Therapeutics Holdings's current Total Liabilities is $11.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current Total Liabilities of $11.46 Mil. The current Total Liabilities is $11.46 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current Total Liabilities is $11.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CERo Therapeutics Holdings Business Description

Address 201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.